Damora Therapeutics (DMRA) Long-Term Deferred Tax (2023 - 2024)
Damora Therapeutics' (DMRA) quarterly Long-Term Deferred Tax came in at $67.2 million in Q4 2024, up 6.02% YoY from $63.4 million in Q1 2024, and up 6.02% on a QoQ basis from $63.4 million in Q4 2023.
Damora Therapeutics (DMRA) Long-Term Deferred Tax (2023 - 2024) Analysis & Trends
Damora Therapeutics (DMRA) has 2 years of Long-Term Deferred Tax data on file, last reported at $67.2 million in Q4 2024.
- Quarterly Long-Term Deferred Tax rose 6.02% year-over-year to $67.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $67.2 million (up 6.02% YoY) and the FY2024 annual result came in at $67.2 million, up 6.02% from the prior year.
- Long-Term Deferred Tax improved to $67.2 million in Q4 2024, from $63.4 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $67.2 million in Q4 2024 to a low of $63.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 67.23 Mn |
| Dec 31, 2023 | 63.41 Mn |